Concomitant monitoring of WT1 and FLT3-ITD expression in FLT3-ITD acute myeloid leukemia patients: which should we trust as a minimal residual disease marker?
Federico De MarchiAnna CandoniMaria Elena ZannierLisa HaleyBonnie Wing Yin LauRenato FaninPublished in: American journal of hematology (2017)